HHS joins international public-private organization to combat antibiotic resistant infections

The U.S. is investing in the effort to combat drug-resistant bacteria through an international partnership including public and private entities, according to the Wall Street Journal.

Researchers have recently stepped up warnings over concerns of antibiotic-resistant infections. This new program, called Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, or CARB-X, will get $250 million from HHS over the next five years.

The partnership will include government research institutions in the U.K. and private labs, drug companies and universities in both countries. The government entities will offer grants to private organizations to research antibiotic resistance to develop new ways to combat bacterial infections.

Check out the Wall Street Journal to see more about how the partnerships will be structured.